Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA

Advanced Drug Delivery Reviews

Volumn 58, Issue 11, 2006, Pages 1203-1223

  Fattal, Elias ^a   Bochot, Amélie ^a  

^a UNIV PARIS SUD   (France)

Author keywords

Antisense oligonucleotides; Aptamers; Cationic lipids; Cationic polymers; Dendrimers; Intravitreal administration; Iontophoresis; Liposomes; Microparticles; Nanoparticles; siRNA

Indexed keywords

DENDRIMERS; DISEASES; DRUG PRODUCTS; ENZYME INHIBITION; RNA; VIRUSES;

ANTISENSE OLIGONUCLEOTIDES; APTAMERS; CATIONIC LIPIDS; CATIONIC POLYMERS; INTRAVITREAL ADMINISTRATION; IONTOPHORESIS; MICROPARTICLES; SIRNA;

NUCLEIC ACIDS;

ANTISENSE OLIGONUCLEOTIDE; APTAMER; FIBROBLAST GROWTH FACTOR; FIBRONECTIN; FOMIVIRSEN; ISIS 13312; LIPOSOME; MICROSPHERE; PEGAPTANIB; POLYESTER; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

CHEMICAL MODIFICATION; CLINICAL TRIAL; CYTOMEGALOVIRUS; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; ENDOPHTHALMITIS; EYE INFLAMMATION; GENE EXPRESSION; HERPES SIMPLEX VIRUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRAOCULAR HYPERTENSION; KERATITIS; NANOPARTICLE; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA TEAR; REVIEW; SUBRETINAL NEOVASCULARIZATION;

EID: 33751172532     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2006.07.020     Document Type: Review

References (135)

1. Perry C.M., and Balfour J.A. Fomivirsen. Drugs 57 (1999) 375-380 (discussion 381)
2. Danis R., Criswell M., Orge F., Wancewicz E., Stecker K., Henry S., and Monia B. Intravitreous anti-raf-1 kinase antisense oligonucleotide as an angioinhibitory agent in porcine preretinal neovascularization. Curr. Eye Res. 26 (2003) 45-54
3. Proske D., Blank M., Buhmann R., and Resch A. Aptamers-basic research, drug development, and clinical applications. Appl. Microbiol. Biotechnol. 69 (2005) 367-374
4. Pestourie C., Tavitian B., and Duconge F. Aptamers against extracellular targets for in vivo applications. Biochimie 87 (2005) 921-930
5. Nimjee S.M., Rusconi C.P., and Sullenger B.A. Aptamers: an emerging class of therapeutics. Annu. Rev. Med. 56 (2005) 555-583
6. Ng E.W., Shima D.T., Calias P., Cunningham Jr. E.T., Guyer D.R., and Adamis A.P. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 5 (2006) 123-132
7. Reich S.J., Fosnot J., Kuroki A., Tang W., Yang X., Maguire A.M., Bennett J., and Tolentino M.J. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vis. 9 (2003) 210-216
8. Kim B., Tang Q., Biswas P.S., Xu J., Schiffelers R.M., Xie F.Y., Ansari A.M., Scaria P.V., Woodle M.C., Lu P., and Rouse B.T. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. Am. J. Pathol. 165 (2004) 2177-2185
9. Tolentino M.J., Brucker A.J., Fosnot J., Ying G.S., Wu I.H., Malik G., Wan S., and Reich S.J. Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina 24 (2004) 132-138
10. Murata M., Takanami T., Shimizu S., Kubota Y., Horiuchi S., Habano W., Ma J.X., and Sato S. Inhibition of ocular angiogenesis by diced small interfering RNAs (siRNAs) specific to vascular endothelial growth factor (VEGF). Curr. Eye Res. 31 (2006) 171-180
11. Bochot A., Mashhour B., Puisieux F., Couvreur P., and Fattal E. Comparison of the ocular distribution of a model oligonucleotide after topical instillation in rabbits of conventional and new dosage forms. J. Drug Target. 6 (1998) 309-313
12. Jager R.D., Aiello L.P., Patel S.C., and Cunningham Jr. E.T. Risks of intravitreous injection: a comprehensive review. Retina 24 (2004) 676-698
13. Loke S.L., Stein C.A., Zhang X.H., Mori K., Nakanishi M., Subasinghe C., Cohen J.S., and Neckers L.M. Characterization of oligonucleotide transport into living cells. Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 3474-3478
14. Hanvey J.C., Peffer N.J., Bisi J.E., Thomson S.A., Cadilla R., Josey J.A., Ricca D.J., Hassman C.F., Bonham M.A., Au K.G., Carter S.G., Bruckenstein D.A., Boyd A.L., Noble S.A., and Babiss L.E. Antisense and antigene properties of peptide nucleic acids. Science 258 (1992) 1481-1485
15. Stein C.A., and Cheng Y.C. Antisense oligonucleotides as therapeutic agents-is the bullet really magical?. Science 261 (1993) 1004-1012
16. Leonetti J.P., Degols G., Clarenc J.P., Mechti N., and Lebleu B. Cell delivery and mechanisms of action of antisense oligonucleotides. Prog. Nucleic Acid Res. Mol. Biol. 44 (1993) 143-166
17. Gewirtz A.M., Sokol D.L., and Ratajczak M.Z. Nucleic acid therapeutics: state of the art and future prospects. Blood 92 (1998) 712-736
18. Opalinska J.B., and Gewirtz A.M. Nucleic-acid therapeutics: basic principles and recent applications. Nat. Rev. Drug Discov. 1 (2002) 503-514
19. Stein C.A. Phosphorothioate antisense oligodeoxynucleotides: questions of specificity. Biotechnology 14 (1996) 47-149
20. Agrawal S. Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochim. Biophys. Acta 1489 (1999) 53-68
21. Gryaznov S.M., Lloyd D.H., Chen J.K., Schultz R.G., DeDionisio L.A., Ratmeyer L., and Wilson W.D. Oligonucleotide N3′→P5′ phosphoramidates. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 5798-5802
22. Gryaznov S., Skorski T., Cucco C., Nieborowska-Skorska M., Chiu C.Y., Lloyd D., Chen J.K., Koziolkiewicz M., and Calabretta B. Oligonucleotide N3′→P5′ phosphoramidates as antisense agents. Nucleic Acids Res. 24 (1996) 1508-1514
23. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. 270 (2003) 1628-1644
24. Urban E., and Noe C.R. Structural modifications of antisense oligonucleotides. Farmaco 58 (2003) 243-258
25. Summerton J., and Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 7 (1997) 187-195
26. Summerton J. Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim. Biophys. Acta 1489 (1999) 141-158
27. Blind M., Kolanus W., and Famulok M. Cytoplasmic RNA modulators of an inside-out signal-transduction cascade. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 3606-3610
28. Burmeister P.E., Lewis S.D., Silva R.F., Preiss J.R., Horwitz L.R., Pendergrast P.S., McCauley T.G., Kurz J.C., Epstein D.M., Wilson C., and Keefe A.D. Direct in vitro selection of a 2′-O-methyl aptamer to VEGF. Chem. Biol. 12 (2005) 25-33
29. Healy J.M., Lewis S.D., Kurz M., Boomer R.M., Thompson K.M., Wilson C., and McCauley T.G. Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm. Res. 21 (2004) 2234-2246
30. Ketting R.F., Fischer S.E., Bernstein E., Sijen T., Hannon G.J., and Plasterk R.H. Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev. 15 (2001) 2654-2659
31. Vaucheret H., and Fagard M. Transcriptional gene silencing in plants: targets, inducers and regulators. Trends Genet. 17 (2001) 29-35
32. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001) 494-498
33. Kretschmer-Kazemi Far R., and Sczakiel G. The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides. Nucleic Acids Res. 31 (2003) 4417-4424
34. Adamis A.P., Miller J.W., Bernal M.T., D'Amico D.J., Folkman J., Yeo T.K., and Yeo K.T. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. 118 (1994) 445-450
35. Pierce E.A., Avery R.L., Foley E.D., Aiello L.P., and Smith L.E. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 905-909
36. Kvanta A., Algvere P.V., Berglin L., and Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest. Ophthalmol. Visual Sci. 37 (1996) 1929-1934
37. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25 (2004) 581-611
38. Robinson G.S., Pierce E.A., Rook S.L., Foley E., Webb R., and Smith L.E. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 4851-4856
39. Garrett K.L., Shen W.Y., and Rakoczy P.E. In vivo use of oligonucleotides to inhibit choroidal neovascularisation in the eye. J. Gene Med. 3 (2001) 373-383
40. Shen W.Y., Garrett K.L., Wang C.G., Zhang K., Ma Z.Z., Constable I.J., and Rakoczy P.E. Preclinical evaluation of a phosphorothioate oligonucleotide in the retina of rhesus monkey. Lab. Invest. 82 (2002) 167-182
41. Hecquet C., Lefevre G., Valtink M., Engelmann K., and Mascarelli F. Activation and role of MAP kinase-dependent pathways in retinal pigment epithelial cells: ERK and RPE cell proliferation. Invest. Ophthalmol. Visual Sci. 43 (2002) 3091-3098
42. Ruckman J., Green L.S., Beeson J., Waugh S., Gillette W.L., Henninger D.D., Claesson-Welsh L., and Janjic N. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem. 273 (1998) 20556-20567
43. Drolet D.W., Nelson J., Tucker C.E., Zack P.M., Nixon K., Bolin R., Judkins M.B., Farmer J.A., Wolf J.L., Gill S.C., and Bendele R.A. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm. Res. 17 (2000) 1503-1510
44. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 22 (2002) 143-152
45. Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 110 (2003) 979-986
46. Cunningham Jr. E.T., Adamis A.P., Altaweel M., Aiello L.P., Bressler N.M., D'Amico D.J., Goldbaum M., Guyer D.R., Katz B., Patel M., and Schwartz S.D. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112 (2005) 1747-1757
47. Ng E.W., and Adamis A.P. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can. J. Ophthalmol. 40 (2005) 352-368
48. Kourlas H., and Schiller D.S. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review. Clin. Ther. 28 (2006) 36-44
49. Gragoudas E.S., Adamis A.P., Cunningham Jr. E.T., Feinsod M., and Guyer D.R. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351 (2004) 2805-2816
50. Larsen M., Sander B., Villumsen J.E., Haamann P.H., la Cour M., and Lund-Andersen H. Treatment of neovascular age-related macular degeneration with intravitreal vascular endothelial growth factor inhibitor-secondary publication. Ugeskr. Laeger 167 (2005) 3301-3305
51. Hariprasad S.M., Shah G.K., and Blinder K.J. Short-term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection. Am. J. Ophthalmol. 141 (2006) 200-201
52. Dhalla M.S., Blinder K.J., Tewari A., Hariprasad S.M., and Apte R.S. Retinal pigment epithelial tear following intravitreal pegaptanib sodium. Am. J. Ophthalmol. 141 (2006) 752-754
53. Shah M., Foreman D.M., and Ferguson M.W. Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J. Cell Sci. 108 Pt 3 (1995) 985-1002
54. Cordeiro M.F., Schultz G.S., Ali R.R., Bhattacharya S.S., and Khaw P.T. Molecular therapy in ocular wound healing. Br. J. Ophthalmol. 83 (1999) 1219-1224
55. Cordeiro M.F. Role of transforming growth factor beta in conjunctival scarring. Clin. Sci. (Lond) 104 (2003) 181-187
56. Cordeiro M.F., Mead A., Ali R.R., Alexander R.A., Murray S., Chen C., York-Defalco C., Dean N.M., Schultz G.S., and Khaw P.T. Novel antisense oligonucleotides targeting TGF-beta inhibit in vivo scarring and improve surgical outcome. Gene Ther. 10 (2003) 59-71
57. Nakamura H., Siddiqui S.S., Shen X., Malik A.B., Pulido J.S., Kumar N.M., and Yue B.Y. RNA interference targeting transforming growth factor-beta type II receptor suppresses ocular inflammation and fibrosis. Mol. Vis. 10 (2004) 703-711
58. McCauley T.G., Kurz J.C., Merlino P.G., Lewis S.D., Gilbert M., Epstein D.M., and Marsh H.N. Pharmacologic and pharmacokinetic assessment of anti-TGFbeta2 aptamers in rabbit plasma and aqueous humor. Pharm. Res. 23 (2006) 303-311
59. Song Q.H., Singh R.P., Richardson T.P., Nugent M.A., and Trinkaus-Randall V. Transforming growth factor-beta1 expression in cultured corneal fibroblasts in response to injury. J. Cell. Biochem. 77 (2000) 186-199
60. Andresen J.L., Ledet T., and Ehlers N. Keratocyte migration and peptide growth factors: the effect of PDGF, bFGF, EGF, IGF-I, aFGF and TGF-beta on human keratocyte migration in a collagen gel. Curr. Eye Res. 16 (1997) 605-613
61. Desire L., Courtois Y., and Jeanny J.C. Endogenous and exogenous fibroblast growth factor 2 support survival of chick retinal neurons by control of neuronal bcl-x(L) and bcl-2 expression through a fibroblast growth factor receptor 1-and ERK-dependent pathway. J. Neurochem. 75 (2000) 151-163
62. Heun Rho S., Seong Yoon H., Won Yoo K., Chan Park W., Hee Jeong J., and Hyun Yoo Y. Antisense basic fibroblast growth factor oligonucleotide reduced adhesion of retinal pigment epithelial cells to extracellular matrix molecules and their proliferation. Ophthalmic Res. 33 (2001) 24-30
63. Kitajima I., Unoki K., and Maruyama I. Phosphorothioate oligodeoxynucleotides inhibit basic fibroblast growth factor-induced angiogenesis in vitro and in vivo. Antisense Nucleic Acid Drug Dev. 9 (1999) 233-239
64. Roy S., Zhang K., Roth T., Vinogradov S., Kao R.S., and Kabanov A. Reduction of fibronectin expression by intravitreal administration of antisense oligonucleotides. Nat. Biotechnol. 17 (1999) 476-479
65. Kulka M., Smith C.C., Aurelian L., Fishelevich R., Meade K., Miller P., and Ts'o P.O. Site specificity of the inhibitory effects of oligo(nucleoside methylphosphonate)s complementary to the acceptor splice junction of herpes simplex virus type 1 immediate early mRNA 4. Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 6868-6872
66. Kulka M., Wachsman M., Miura S., Fishelevich R., Miller P.S., Ts'o P.O., and Aurelian L. Antiviral effect of oligo(nucleoside methylphosphonates) complementary to the herpes simplex virus type 1 immediate early mRNAs 4 and 5. Antivir. Res. 20 (1993) 115-130
67. Kulka M., Smith C.C., Levis J., Fishelevich R., Hunter J.C., Cushman C.D., Miller P.S., Ts'o P.O., and Aurelian L. Synergistic antiviral activities of oligonucleoside methylphosphonates complementary to herpes simplex virus type 1 immediate-early mRNAs 4, 5, and 1. Antimicrob. Agents Chemother. 38 (1994) 675-680
68. Kulka M., and Aurelian L. Antiviral activity of an oligo(nucleoside methylphosphonate) that targets HSV-1 immediate-early pre-mRNA 4,5 is augmented by cotreatment with replication-defective adenovirus. Antisense Res. Dev. 5 (1995) 243-249
69. Kean J.M., Kipp S.A., Miller P.S., Kulka M., and Aurelian L. Inhibition of herpes simplex virus replication by antisense oligo-2′-O-methylribonucleoside methylphosphonates. Biochemistry 34 (1995) 14617-14620
70. Poddevin B., Meguenni S., Elias I., Vasseur M., and Blumenfeld M. Improved anti-herpes simplex virus type 1 activity of a phosphodiester antisense oligonucleotide containing a 3′-terminal hairpin-like structure. Antisense Res. Dev. 4 (1994) 147-154
71. Peyman A., Helsberg M., Kretzschmar G., Mag M., Grabley S., and Uhlmann E. Inhibition of viral growth by antisense oligonucleotides directed against the IE110 and the UL30 mRNA of herpes simplex virus type-1. Biol. Chem. Hoppe-Seyler 376 (1995) 195-198
72. Flores-Aguilar M., Besen G., Vuong C., Tatebayashi M., Munguia D., Gangan P., Wiley C.A., and Freeman W.R. Evaluation of retinal toxicity and efficacy of anti-cytomegalovirus and anti-herpes simplex virus antiviral phosphorothioate oligonucleotides ISIS 2922 and ISIS 4015. J. Infect. Dis. 175 (1997) 1308-1316
73. Wasmuth S., Bauer D., Yang Y., Steuhl K.P., and Heiligenhaus A. Topical treatment with antisense oligonucleotides targeting tumor necrosis factor-alpha in herpetic stromal keratitis. Invest. Ophthalmol. Visual Sci. 44 (2003) 5228-5234
74. Azad R.F., Driver V.B., Tanaka K., Crooke R.M., and Anderson K.P. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob. Agents Chemother. 37 (1993) 1945-1954
75. Azad R.F., Brown-Driver V., Buckheit Jr. R.W., and Anderson K.P. Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs. Antivir. Res. 28 (1995) 101-111
76. Anderson K.P., Fox M.C., Brown-Driver V., Martin M.J., and Azad R.F. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA. Antimicrob. Agents Chemother. 40 (1996) 2004-2011
77. Mulamba G.B., Hu A., Azad R.F., Anderson K.P., and Coen D.M. Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922). Antimicrob. Agents Chemother. 42 (1998) 971-973
78. Henry S.P., Miner R.C., Drew W.L., Fitchett J., York-Defalco C., Rapp L.M., and Levin A.A. Antiviral activity and ocular kinetics of antisense oligonucleotides designed to inhibit CMV replication. Invest. Ophthalmol. Visual Sci. 42 (2001) 2646-2651
79. Detrick B., Nagineni C.N., Grillone L.R., Anderson K.P., Henry S.P., and Hooks J.J. Inhibition of human cytomegalovirus replication in a human retinal epithelial cell model by antisense oligonucleotides. Invest. Ophthalmol. Visual Sci. 42 (2001) 163-169
80. Pari G.S., and Anders D.G. Eleven loci encoding trans-acting factors are required for transient complementation of human cytomegalovirus oriLyt-dependent DNA replication. J. Virol. 67 (1993) 6979-6988
81. Pari G.S., Field A.K., and Smith J.A. Potent antiviral activity of an antisense oligonucleotide complementary to the intron-exon boundary of human cytomegalovirus genes UL36 and UL37. Antimicrob. Agents Chemother. 39 (1995) 1157-1161
82. Smith J.A., and Pari G.S. Expression of human cytomegalovirus UL36 and UL37 genes is required for viral DNA replication. J. Virol. 69 (1995) 1925-1931
83. Hämäläinen K.M., Kananen K., Auriola S., Kontturi K., and Urtti A. Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera. Invest. Ophthalmol. Visual Sci. 38 (1997) 627-634
84. Asahara T., Shinomiya K., Naito T., and Shiota H. Induction of gene into the rabbit eye by iontophoresis: preliminary report. Jpn. J. Ophthalmol. 45 (2001) 31-39
85. Berdugo M., Valamanesh F., Andrieu C., Klein C., Benezra D., Courtois Y., and Behar-Cohen F. Delivery of antisense oligonucleotide to the cornea by iontophoresis. Antisense Nucleic Acid Drug Dev. 13 (2003) 107-114
86. Olsen T.W., Edelhauser H.F., Lim J.I., and Geroski D.H. Human scleral permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest. Ophthalmol. Visual Sci. 36 (1995) 1893-1903
87. Ambati J., Canakis C.S., Miller J.W., Gragoudas E.S., Edwards A., Weissgold D.J., Kim I., Delori F.C., and Adamis A.P. Diffusion of high molecular weight compounds through sclera. Invest. Ophthalmol. Visual Sci. 41 (2000) 1181-1185
88. Ambati J., Gragoudas E.S., Miller J.W., You T.T., Miyamoto K., Delori F.C., and Adamis A.P. Transscleral delivery of bioactive protein to the choroid and retina. Invest. Ophthalmol. Visual Sci. 41 (2000) 1186-1191
89. Shuler Jr. R.K., Dioguardi P.K., Henjy C., Nickerson J.M., Cruysberg L.P., and Edelhauser H.F. Scleral permeability of a small, single-stranded oligonucleotide. J. Ocular Pharmacol. Ther. 20 (2004) 159-168
90. Carrasquillo K.G., Ricker J.A., Rigas I.K., Miller J.W., Gragoudas E.S., and Adamis A.P. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. Invest. Ophthalmol. Visual Sci. 44 (2003) 290-299
91. Halhal M., Renard G., Courtois Y., BenEzra D., and Behar-Cohen F. Iontophoresis: from the lab to the bed side. Exp. Eye Res. 78 (2004) 751-757
92. Myles M.E., Neumann D.M., and Hill J.M. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Adv. Drug Deliv. Rev. 57 (2005) 2063-2079
93. Voigt M., de Kozak Y., Halhal M., Courtois Y., and Behar-Cohen F. Down-regulation of NOSII gene expression by iontophoresis of anti-sense oligonucleotide in endotoxin-induced uveitis. Biochem. Biophys. Res. Commun. 295 (2002) 336-341
94. Boussif O., Lezoualc'h F., Zanta M.A., Mergny M.D., Scherman D., Demeneix B., and Behr J.P. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 7297-7301
95. Demeneix B., Behr J., Boussif O., Zanta M.A., Abdallah B., and Remy J. Gene transfer with lipospermines and polyethylenimines. Adv. Drug Deliv. Rev. 30 (1998) 85-95
96. Jaaskelainen I., Lappalainen K., Honkakoski P., and Urtti A. Requirements for delivery of active antisense oligonucleotides into cells with lipid carriers. Methods Enzymol. 387 (2004) 210-230
97. Urtti A., Polansky J., Lui G.M., and Szoka F.C. Gene delivery and expression in human retinal pigment epithelial cells: effects of synthetic carriers, serum, extracellular matrix and viral promoters. J. Drug Target. 7 (2000) 413-421
98. Abul-Hassan K., Walmsley R., and Boulton M. Optimization of non-viral gene transfer to human primary retinal pigment epithelial cells. Curr. Eye Res. 20 (2000) 361-366
99. Jaaskelainen I., Peltola S., Honkakoski P., Monkkonen J., and Urtti A. A lipid carrier with a membrane active component and a small complex size are required for efficient cellular delivery of anti-sense phosphorothioate oligonucleotides. Eur. J. Pharm. Sci. 10 (2000) 187-193
100. Gomes dos Santos A.L., Bochot A., Tsapis N., Artzner F., Bejjani R.A., Thillaye-Goldenberg B., de Kozak Y., Fattal E., and Behar-Cohen F. Oligonucleotide-polyethylenimine complexes targeting retinal cells: structural analysis and application to anti-TGFbeta-2 therapy. Pharm. Res. 23 (2006) 770-781
101. Normand N., van Leeuwen H., and O'Hare P. Particle formation by a conserved domain of the herpes simplex virus protein VP22 facilitating protein and nucleic acid delivery. J. Biol. Chem. 276 (2001) 15042-15050
102. Zavaglia D., Normand N., Brewis N., O'Hare P., Favrot M.C., and Coll J.L. VP22-mediated and light-activated delivery of an anti-c-raf1 antisense oligonucleotide improves its activity after intratumoral injection in nude mice. Mol. Ther. 8 (2003) 840-845
103. Normand N., Valamanesh F., Savoldelli M., Mascarelli F., BenEzra D., Courtois Y., and Behar-Cohen F. VP22 light controlled delivery of oligonucleotides to ocular cells in vitro and in vivo. Mol. Vis. 11 (2005) 184-191
104. Marano R.J., and Rakoczy P.E. Treatments for choroidal and retinal neovascularization: a focus on oligonucleotide therapy and delivery for the regulation of gene function. Clin. Experiment Ophthalmol. 33 (2005) 81-89
105. Dennig J., and Duncan E. Gene transfer into eukaryotic cells using activated polyamidoamine dendrimers. J. Biotechnol. 90 (2002) 339-347
106. Al-Jamal K.T., Ramaswamy C., and Florence A.T. Supramolecular structures from dendrons and dendrimers. Adv. Drug Deliv. Rev. 57 (2005) 2238-2270
107. Wimmer N., Marano R.J., Kearns P.S., Rakoczy E.P., and Toth I. Syntheses of polycationic dendrimers on lipophilic peptide core for complexation and transport of oligonucleotides. Bioorg. Med. Chem. Lett. 12 (2002) 2635-2637
108. Marano R.J., Wimmer N., Kearns P.S., Thomas B.G., Toth I., Brankov M., and Rakoczy P.E. Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide. Exp. Eye Res. 79 (2004) 525-535
109. Pitkanen L., Pelkonen J., Ruponen M., Ronkko S., and Urtti A. Neural retina limits the nonviral gene transfer to retinal pigment epithelium in an in vitro bovine eye model. AAPS J. 6 (2004) e25
110. Pitkanen L., Ruponen M., Nieminen J., and Urtti A. Vitreous is a barrier in nonviral gene transfer by cationic lipids and polymers. Pharm. Res. 20 (2003) 576-583
111. Ruponen M., Yla-Herttuala S., and Urtti A. Interactions of polymeric and liposomal gene delivery systems with extracellular glycosaminoglycans: physicochemical and transfection studies. Biochim. Biophys. Acta 1415 (1999) 331-341
112. Ruponen M., Ronkko S., Honkakoski P., Pelkonen J., Tammi M., and Urtti A. Extracellular glycosaminoglycans modify cellular trafficking of lipoplexes and polyplexes. J. Biol. Chem. 276 (2001) 33875-33880
113. Ruponen M., Honkakoski P., Ronkko S., Pelkonen J., Tammi M., and Urtti A. Extracellular and intracellular barriers in non-viral gene delivery. J. Control. Release 93 (2003) 213-217
114. Peeters L., Sanders N.N., Braeckmans K., Boussery K., Van de Voorde J., De Smedt S.C., and Demeester J. Vitreous: a barrier to nonviral ocular gene therapy. Invest. Ophthalmol. Visual Sci. 46 (2005) 3553-3561
115. Marano R.J., Wimmer N., Kearns P.S., Thomas B.G., Toth I., Wilson A.S., Brankov M., and Rakoczy P.E. Use of synthetic dendrimer peptide's to mediate the delivery of a sense oligonucleotide. Invest. Ophthalmol. Visual Sci. 44 (2003) 1078
116. Marano R.J., Toth I., Wimmer N., Brankov M., and Rakoczy P.E. Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Ther. 12 (2005) 1544-1550
117. Bochot A., Couvreur P., and Fattal E. Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery. Prog. Retin. Eye Res. 19 (2000) 131-147
118. Fitzgerald P., Hadgraft J., and Wilson C.G. A gamma scintigraphic evaluation of the precorneal residence of liposomal formulations in the rabbit. J. Pharm. Pharmacol. 39 (1987) 487-490
119. Bochot A., Fattal E., Boutet V., Deverre J.R., Jeanny J.C., Chacun H., and Couvreur P. Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Invest. Ophthalmol. Visual Sci. 43 (2002) 253-259
120. Ogata N., Otsuji T., Matsushima M., Kimoto T., Yamanaka R., Takahashi K., Wada M., Uyama M., and Kaneda Y. Phosphorothioate oligonucleotides induction into experimental choroidal neovascularization by HVJ-liposome system. Curr. Eye Res. 18 (1999) 261-269
121. Moritera T., Ogura Y., Honda Y., Wada R., Hyon S.H., and Ikada Y. Microspheres of biodegradable polymers as a drug-delivery system in the vitreous. Invest. Ophthalmol. Visual Sci. 32 (1991) 1785-1790
122. Giordano G.G., Chevez-Barrios P., Refojo M.F., and Garcia C.A. Biodegradation and tissue reaction to intravitreous biodegradable poly(d,l-lactic-co-glycolic)acid microspheres. Curr. Eye Res. 14 (1995) 761-768
123. Bourges J.L., Gautier S.E., Delie F., Bejjani R.A., Jeanny J.C., Gurny R., BenEzra D., and Behar-Cohen F.F. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest. Ophthalmol. Visual Sci. 44 (2003) 3562-3569
124. Moshfeghi A.A., and Peyman G.A. Micro- and nanoparticulates. Adv. Drug Deliv. Rev. 57 (2005) 2047-2052
125. Bejjani R.A., BenEzra D., Cohen H., Rieger J., Andrieu C., Jeanny J.C., Gollomb G., and Behar-Cohen F.F. Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol. Vis. 11 (2005) 124-132
126. Arnedo A., Irache J.M., Merodio M., and Espuelas Millan M.S. Albumin nanoparticles improved the stability, nuclear accumulation and anticytomegaloviral activity of a phosphodiester oligonucleotide. J. Control. Release 94 (2004) 217-227
127. Arnedo A., Campanero M.A., Espuelas S., Renedo M.J., and Irache J.M. Determination of oligonucleotide ISIS 2922 in nanoparticulate delivery systems by capillary zone electrophoresis. J. Chromatogr., A 871 (2000) 311-320
128. Irache J.M., Merodio M., Arnedo A., Camapanero M.A., Mirshahi M., and Espuelas S. Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugs. Mini Rev. Med. Chem. 5 (2005) 293-305
129. Khan A., Sommer W., Fuxe K., and Akhtar S. Site-specific administration of antisense oligonucleotides using biodegradable polymer microspheres provides sustained delivery and improved subcellular biodistribution in the neostriatum of the rat brain. J. Drug Target. 8 (2000) 319-334
130. De Rosa G., Quaglia F., La Rotonda M., Besnard M., and Fattal E. Biodegradable microparticles for the controlled delivery of oligonucleotides. Int. J. Pharm. 242 (2002) 225-228
131. De Rosa G., Quaglia F., La Rotonda M.I., Appel M., Alphandary H., and Fattal E. Poly(lactide-co-glycolide) microspheres for the controlled release of oligonucleotide/polyethylenimine complexes. J. Pharm. Sci. 91 (2002) 790-799
132. Delie F., Berton M., Allemann E., and Gurny R. Comparison of two methods of encapsulation of an oligonucleotide into poly(d,l-lactic acid) particles. Int. J. Pharm. 214 (2001) 25-30
133. De Rosa G., Bochot A., Quaglia F., Besnard M., and Fattal E. A new delivery system for antisense therapy: PLGA microspheres encapsulating oligonucleotide/polyethyleneimine solid complexes. Int. J. Pharm. 254 (2003) 89-93
134. De Rosa G., Quaglia F., Bochot A., Ungaro F., and Fattal E. Long-term release and improved intracellular penetration of oligonucleotide-polyethylenimine complexes entrapped in biodegradable microspheres. Biomacromolecules 4 (2003) 529-536
135. Gomes Dos Santos A.L., Bochot A., Doyle A., Tsapis N., Siepmann J., Siepmann F., Schmaler J., Besnard M., Behar-Cohen F., and Fattal E. Sustained release of nanosized complexes of polyethylenimine and anti-TGF-beta2 oligonucleotide improves the outcome of glaucoma surgery. J. Control. Release 112 (2006) 369-381